-transparent.png){kind=logo}
(S)-UH-301 [(S)-5-fluoro-8-hydroxy-2-(dipropylamino)-tetralin, 0.5-4.0 mg/kg i.v.] did not significantly alter the firing rate of 5-hydroxytryptamine (5-HT) containing neurons in the dorsal raphe nucleus (DRN) as a group, although some individual cells were activated whereas others were depressed. However, (S)-UH-301 (2.0 mg/kg i.v.) consistently reversed the inhibition of DRN-5-HT cells produced by the selective 5-HT1A receptor agonist (R)-8-OH-DPAT (0.5 microgram/kg i.v.) and the dose-response curve for this effect of (R)-8-OH-DPAT was markedly shifted to the right by pretreatment with (S)-UH-301 (1.0 mg/kg i.v.). These results support the notion that (S)-UH-301 acts as an antagonist at central 5-HT1A receptors.
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
June 1992,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
September 1991,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
July 1991,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
September 1986,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
January 1989,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
October 1994,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
April 2002,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
February 1997,
Synapse (New York, N.Y.),
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
April 1998,
European journal of pharmacology,
L Arborelius, and
B B Höök, and
U Hacksell, and
T H Svensson
June 1992,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
